Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

85.45 +0.85 (+1.00%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,139,667
Open 84.65
Bid (Size) 85.45 (200)
Ask (Size) 85.50 (1,300)
Prev. Close 84.60
Today's Range 83.45 - 85.47
52wk Range 23.95 - 86.74
Shares Outstanding 141,797,854
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ionis Pharmaceuticals (NASDAQ:IONS) Shows High Technical and Setup Ratings for Potential Breakout ↗
Via Chartmill
News headline image
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+7.3%
+7.3%
1 Month
+5.5%
+5.5%
3 Month
+8.8%
+8.8%
6 Month
+104.3%
+104.3%
1 Year
+168.0%
+168.0%

More News

Read More
News headline image
Ionis updates time for fourth quarter and full year 2025 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
Via Finterra
Topics Economy Intellectual Property
IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Shows High-Quality Technical Breakout Setup ↗
Via Chartmill
News headline image
Ionis to hold fourth quarter and full year 2025 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
News headline image
What a $20 Million Bet on a Stock Down 3% Signals for Investors ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Autoliv Stock Is Up 32% in a Year, But One Fund Just Cut $3.8 Million ↗
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
News headline image
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500
Via PredictStreet
Topics Economy Intellectual Property Stocks
News headline image
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Completes Acquisition of Alcyone Therapeutics
From Biogen Inc.
Via GlobeNewswire
News headline image
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce ↗
Via Benzinga
News headline image
Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug ↗
Via Benzinga

Frequently Asked Questions

Is Ionis Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Ionis Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Ionis Pharmaceuticals, Inc. - Common Stock trade on?
Ionis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock is IONS on the Nasdaq Stock Market
What is the current price of Ionis Pharmaceuticals, Inc. - Common Stock?
The current price of Ionis Pharmaceuticals, Inc. - Common Stock is 85.45
When was Ionis Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Ionis Pharmaceuticals, Inc. - Common Stock was at 02/24/26 04:00 PM ET
What is the market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock is 12.12B
How many shares of Ionis Pharmaceuticals, Inc. - Common Stock are outstanding?
Ionis Pharmaceuticals, Inc. - Common Stock has 12B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.